Please try another search
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes. The company is also developing GX-188E that is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is headquartered in Seoul, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Young-Chul Sung | 67 | 2022 | Founder & Chairman of the Scientific Advisory Board |
Young-Jin Kim | 67 | 2022 | Chairman of BOD |
Myeonghee Yu | - | 2022 | Member of Scientific Advisory Board |
Keon Pai Jin | - | 2022 | Non-Executive Director |
Munseok Gang | - | 2022 | Member of Scientific Advisory Board |
Jinhyung Gang | - | 2022 | Member of Scientific Advisory Board |
Mijung Ahn | - | 2022 | Member of Scientific Advisory Board |
Chul Jun Hyun | - | 2022 | Auditor & Director |
Peter Laivins | - | 2022 | Director |
Heeseop Shin | - | 2022 | Member of Scientific Advisory Board |
EuiCheol Shin | - | 2022 | Member of Scientific Advisory Board |
Sung-June Hong | - | 2022 | Executive VP, CFO & Director |
Hyeok Jong Lee | - | 2022 | Director |
Jungwon Woo | - | 2022 | President & Director |
Neil K. Warma | 61 | 2022 | President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review